VSV cDNA libraries for cancer immuno/virotherapy

Mayo Clinic researchers have developed a novel technology to define new repertoires of tumor antigen(s) which work alone or in combination to generate anti-tumor immune responses. Definition of arrays of antigens which co-operate in vivo to cure established tumors will inform future strategies for novel clinical vaccines through the use of vesicular stomatis virus (VSV) with cDNA libraries constructed with selected, relevant and defined epitopes which can be readily manufactured for clinical use. This technology can be applied for the treatment of a broad range of different cancer types as well as to antigen discovery in diseases where pathology is induced by immune reactivity against a single or multiple target antigens. Researchers have specifically demonstrated that VSV that encodes N-Ras, cytochrome c (ctyc) and Tyrosinase-related protein 1(TYRP1), can be used to treat melanoma.